source · text/markdown
source_317afbca6c59431e
sha256 4065febeb2f1e18b93b23b7adc07a07a7d20206c6e2ca42ecf2551d332204e62
by researka:v2 · 2026-07-15 12:04:56.907342+04:00
# Metformin Hepatocellular Carcinoma Versus Neurodegenerative Disease ## Signal Metformin is associated with a reduced odds ratio of hepatocellular carcinoma in diabetic patients. [R1] ## Update Metformin shows no significant effect on the incidence of neurodegenerative disease subtypes. [R2] ## Synthesis The divergence in outcomes is defined by the contrast between hepatocellular carcinoma in diabetic populations and neurodegenerative disease subtypes. [R1] [R2] ## Limitations Evidence is limited by observational designs, lack of head-to-head comparison, and unspecified dose, duration, and aggregation constraints. [R1] [R2] ## Falsifier A result showing no significant association between metformin and hepatocellular carcinoma would overturn the divergence. [R1] [R2] ## Receipts - [R1] Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review (2019). DOI: 10.1016/j.aohep.2019.10.005. - [R2] Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis (2020). DOI: 10.1136/bmjdrc-2020-001370. ## Status Receipt-bound alpha memo. Every factual claim is source-bound; the falsifier is a test, not evidence.
metadata
{
"article_type": "alpha_memo",
"domain_slug": "longevity_research",
"researka_object_type": "submission",
"researka_submission_id": "928f3496-a480-4982-918f-5644fd7bd520",
"title": "Metformin Hepatocellular Carcinoma Versus Neurodegenerative Disease"
}